Promyelocytic leukemia-retinoic acid receptor alpha (PML-RARα) expression in acute promyelocytic leukemia (APL) impairs transforming growth factor beta (TGFβ) signaling, leading to cell growth advantage. Halofuginone (HF), a low-molecular-weight alkaloid that modulates TGFβ signaling, was used to treat APL cell lines and non-obese diabetic/severe combined immunodeficiency (NOD/SCID) mice subjected to transplantation with leukemic cells from human chorionic gonadotrophin-PML-RARα transgenic mice (TG). Cell cycle analysis using incorporated bromodeoxyuridine and 7-amino-actinomycin D showed that, in NB4 and NB4-R2 APL cell lines, HF inhibited cellular proliferation (P<0.001) and induced apoptosis (P = 0.002) after a 24-hour incubation. Addition of TGFβ revealed that NB4 cells were resistant to its growth-suppressive effects and that HF induced these effects in the presence or absence of the cytokine. Cell growth inhibition was associated with up-regulation of TGFβ target genes involved in cell cycle regulation (TGFB, TGFBRI, SMAD3, p15, and p21) and down-regulation of MYC. Additionally, TGFβ protein levels were decreased in leukemic TG animals and HF in vivo could restore TGFβ values to normal. To test the in vivo anti-leukemic activity of HF, we transplanted NOD/SCID mice with TG leukemic cells and treated them with HF for 21 days. HF induced partial hematological remission in the peripheral blood, bone marrow, and spleen. Together, these results suggest that HF has anti-proliferative and anti-leukemic effects by reversing the TGFβ blockade in APL. Since loss of the TGFβ response in leukemic cells may be an important second oncogenic hit, modulation of TGFβ signaling may be of therapeutic interest.
References
[1]
Siegel PM, Massague J (2003) Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer. Nat Rev Cancer 3: 807–821.
[2]
Shi Y, Massague J (2003) Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 113: 685–700.
[3]
Nakao A, Imamura T, Souchelnytskyi S, Kawabata M, Ishisaki A, et al. (1997) TGF-beta receptor-mediated signalling through Smad2, Smad3 and Smad4. EMBO J 16: 5353–5362.
[4]
Roberts AB (1999) TGF-beta signaling from receptors to the nucleus. Microbes Infect 1: 1265–1273.
[5]
Chen CR, Kang Y, Massague J (2001) Defective repression of c-myc in breast cancer cells: A loss at the core of the transforming growth factor beta growth arrest program. Proc Natl Acad Sci U S A 98: 992–999.
[6]
Siegel PM, Shu W, Cardiff RD, Muller WJ, Massague J (2003) Transforming growth factor beta signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis. Proc Natl Acad Sci U S A 100: 8430–8435.
[7]
Roberts AB, Wakefield LM (2003) The two faces of transforming growth factor beta in carcinogenesis. Proc Natl Acad Sci U S A 100: 8621–8623.
[8]
Jakubowiak A, Pouponnot C, Berguido F, Frank R, Mao S, et al. (2000) Inhibition of the transforming growth factor beta 1 signaling pathway by the AML1/ETO leukemia-associated fusion protein. J Biol Chem 275: 40282–40287.
[9]
Kim SJ, Letterio J (2003) Transforming growth factor-beta signaling in normal and malignant hematopoiesis. Leukemia 17: 1731–1737.
[10]
Gutierrez NC, Lopez-Perez R, Hernandez JM, Isidro I, Gonzalez B, et al. (2005) Gene expression profile reveals deregulation of genes with relevant functions in the different subclasses of acute myeloid leukemia. Leukemia 19: 402–409.
[11]
Raza A, Yousuf N, Abbas A, Umerani A, Mehdi A, et al. (1992) High expression of transforming growth factor-beta long cell cycle times and a unique clustering of S-phase cells in patients with acute promyelocytic leukemia. Blood 79: 1037–1048.
[12]
Lin HK, Bergmann S, Pandolfi PP (2004) Cytoplasmic PML function in TGF-beta signalling. Nature 431: 205–211.
[13]
Lin HK, Bergmann S, Pandolfi PP (2005) Deregulated TGF-beta signaling in leukemogenesis. Oncogene 24: 5693–5700.
[14]
Xavier S, Piek E, Fujii M, Javelaud D, Mauviel A, et al. (2004) Amelioration of radiation-induced fibrosis: inhibition of transforming growth factor-beta signaling by halofuginone. J Biol Chem 279: 15167–15176.
[15]
Gross DJ, Reibstein I, Weiss L, Slavin S, Dafni H, et al. (2003) Treatment with halofuginone results in marked growth inhibition of a von Hippel-Lindau pheochromocytoma in vivo. Clin Cancer Res 9: 3788–3793.
[16]
Abramovitch R, Itzik A, Harel H, Nagler A, Vlodavsky I, et al. (2004) Halofuginone inhibits angiogenesis and growth in implanted metastatic rat brain tumor model–an MRI study. Neoplasia 6: 480–489.
[17]
Taras D, Blanc JF, Rullier A, Dugot-Senant N, Laurendeau I, et al. (2006) Halofuginone suppresses the lung metastasis of chemically induced hepatocellular carcinoma in rats through MMP inhibition. Neoplasia 8: 312–318.
[18]
Lanotte M, Martin-Thouvenin V, Najman S, Balerini P, Valensi F, et al. (1991) NB4, a maturation inducible cell line with t(15;17) marker isolated from a human acute promyelocytic leukemia (M3). Blood 77: 1080–1086.
[19]
Duprez E, Benoit G, Flexor M, Lillehaug JR, Lanotte M (2000) A mutated PML/RARA found in the retinoid maturation resistant NB4 subclone, NB4-R2, blocks RARA and wild-type PML/RARA transcriptional activities. Leukemia 14: 255–261.
[20]
Schreiber G, Schreiber M (1973) The preparation of single cell suspensions from liver and their use for the study of protein synthesis. Subcell Biochem 2: 307–353.
[21]
Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248–254.
[22]
Towbin H, Staehelin T, Gordon J (1979) Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A 76: 4350–4354.
[23]
He LZ, Tribioli C, Rivi R, Peruzzi D, Pelicci PG, et al. (1997) Acute leukemia with promyelocytic features in PML/RARalpha transgenic mice. Proc Natl Acad Sci U S A 94: 5302–5307.
[24]
Rego EM, Ruggero D, Tribioli C, Cattoretti G, Kogan S, et al. (2006) Leukemia with distinct phenotypes in transgenic mice expressing PML/RAR alpha, PLZF/RAR alpha or NPM/RAR alpha. Oncogene 25: 1974–1979.
[25]
Gavish Z, Pinthus JH, Barak V, Ramon J, Nagler A, et al. (2002) Growth inhibition of prostate cancer xenografts by halofuginone. Prostate 51: 73–83.
[26]
McGaha TL, Phelps RG, Spiera H, Bona C (2002) Halofuginone, an inhibitor of type-I collagen synthesis and skin sclerosis, blocks transforming-growth-factor-beta-mediated Smad3 activation in fibroblasts. J Invest Dermatol 118: 461–470.
[27]
Nagler A, Ohana M, Shibolet O, Shapira MY, Alper R, et al. (2004) Suppression of hepatocellular carcinoma growth in mice by the alkaloid coccidiostat halofuginone. Eur J Cancer 40: 1397–1403.
[28]
Sheffer Y, Leon O, Pinthus JH, Nagler A, Mor Y, et al. (2007) Inhibition of fibroblast to myofibroblast transition by halofuginone contributes to the chemotherapy-mediated antitumoral effect. Mol Cancer Ther 6: 570–577.
[29]
van Dongen JJ, Macintyre EA, Gabert JA, Delabesse E, Rossi V, et al. (1999) Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia 13: 1901–1928.
[30]
Kogan SC, Ward JM, Anver MR, Berman JJ, Brayton C, et al. (2002) Bethesda proposals for classification of nonlymphoid hematopoietic neoplasms in mice. Blood 100: 238–245.
[31]
Elkin M, Miao HQ, Nagler A, Aingorn E, Reich R, et al. (2000) Halofuginone: a potent inhibitor of critical steps in angiogenesis progression. FASEB J 14: 2477–2485.
[32]
Leiba M, Cahalon L, Shimoni A, Lider O, Zanin-Zhorov A, et al. (2006) Halofuginone inhibits NF-kappaB and p38 MAPK in activated T cells. J Leukoc Biol 80: 399–406.
[33]
Stecklair KP, Hamburger DR, Egorin MJ, Parise RA, Covey JM, et al. (2001) Pharmacokinetics and tissue distribution of halofuginone (NSC 713205) in CD2F1 mice and Fischer 344 rats. Cancer Chemother Pharmacol 48: 375–382.
[34]
Kim SJ, Angel P, Lafyatis R, Hattori K, Kim KY, et al. (1990) Autoinduction of transforming growth factor beta 1 is mediated by the AP-1 complex. Mol Cell Biol 10: 1492–1497.
[35]
Casini T, Pelicci PG (1999) A function of p21 during promyelocytic leukemia cell differentiation independent of CDK inhibition and cell cycle arrest. Oncogene 18: 3235–3243.
[36]
Yagi K, Furuhashi M, Aoki H, Goto D, Kuwano H, et al. (2002) c-myc is a downstream target of the Smad pathway. J Biol Chem 277: 854–861.
[37]
Derynck R, Akhurst RJ, Balmain A (2001) TGF-beta signaling in tumor suppression and cancer progression. Nat Genet 29: 117–129.
[38]
Fortunel NO, Hatzfeld A, Hatzfeld JA (2000) Transforming growth factor-beta: pleiotropic role in the regulation of hematopoiesis. Blood 96: 2022–2036.
[39]
Gnainsky Y, Kushnirsky Z, Bilu G, Hagai Y, Genina O, et al. (2007) Gene expression during chemically induced liver fibrosis: effect of halofuginone on TGF-beta signaling. Cell Tissue Res 328: 153–166.
[40]
Zion O, Genin O, Kawada N, Yoshizato K, Roffe S, et al. (2009) Inhibition of transforming growth factor beta signaling by halofuginone as a modality for pancreas fibrosis prevention. Pancreas 38: 427–435.
[41]
Sundrud MS, Koralov SB, Feuerer M, Calado DP, Kozhaya AE, et al. (2009) Halofuginone inhibits TH17 cell differentiation by activating the amino acid starvation response. Science 324: 1334–1338.
[42]
Wu C, Wang S, Wang F, Chen Q, Peng S, et al. (2009) Increased frequencies of T helper type 17 cells in the peripheral blood of patients with acute myeloid leukaemia. Clin Exp Immunol 158: 199–204.
